Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
J BUON
; 22(2): 334-339, 2017.
Article
en En
| MEDLINE
| ID: mdl-28534353
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Receptor ErbB-2
/
Trastuzumab
/
Antineoplásicos
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2017
Tipo del documento:
Article